IP Verse

Etherna Immunotherapies Nv opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Etherna Immunotherapies Nv

Patent Number:
EP3590949
Title:
Ribonucleic Acids Containing N1-Methyl-Pseudouracils And Uses Thereof
Applicant:
MODERNATX, INC.
Opposition Date:
Feb 20, 2023
Patent Number:
EP2791160
Title:
Modified Nucleoside, Nucleotide, And Nucleic Acid Compositions
Applicant:
MODERNA THERAPEUTICS, INC.
Opposition Date:
Dec 2, 2022
Patent Number:
EP3682905
Title:
Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses Thereof
Applicant:
MODERNATX, INC.
Opposition Date:
Aug 31, 2022
Patent Number:
EP3173092
Title:
Rna Containing Composition For Treatment Of Tumor Diseases
Applicant:
CUREVAC AG
Opposition Date:
Mar 26, 2020
Patent Number:
EP3153179
Title:
Optimised Injection Formulation For Mrna
Applicant:
CUREVAC AG
Opposition Date:
Mar 18, 2020
Patent Number:
EP3292873
Title:
Combination Of Vaccination And Inhibition Of The Pd-1 Pathway
Applicant:
CUREVAC AG
Opposition Date:
Feb 3, 2020
Patent Number:
EP2216028
Title:
Immunostimulation By Chemically Modified Rna
Applicant:
CUREVAC AG
Opposition Date:
Sep 6, 2018
Patent Number:
EP2958588
Title:
Combination Of Vaccination And Inhibition Of The Pd-1 Pathway
Applicant:
CUREVAC AG
Opposition Date:
May 23, 2018

Competitors of Etherna Immunotherapies Nv

CUREVAC AG

CUREVAC SE

MODERNATX, INC.

Want to track Etherna Immunotherapies Nv?

Feel free to send us a message here and we will get back to you